BioMaxima S.A. Logo

BioMaxima S.A.

Manufacturer of IVD solutions including tests, reagents, and equipment for medical labs.

BMX | WAR

Overview

Corporate Details

ISIN(s):
PLBIOMX00015
LEI:
2594007GAALFMXP4YB89
Country:
Poland
Address:
Lublin Vetterów 5, 20-277 Lublin
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BioMaxima S.A. is a manufacturer in the biotechnology sector specializing in the in vitro diagnostics (IVD) market. The company develops and produces a comprehensive range of solutions for laboratory diagnostics, supporting medical professionals and diagnosticians. Its portfolio encompasses microbiological media, reagents, specialized equipment, and IVD tests. Key application areas include clinical chemistry, haematology, and the diagnosis of infectious diseases, featuring systems for determining drug sensitivity and reference strains for microorganisms.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-27 12:45
Regulatory News Service
Informacja o otrzymaniu dofinansowania w kwocie 1.097.835,17 zł na rozbudowę of…
Polish 1.7 KB
2025-08-08 20:29
Director's Dealing
Zawiadomienie 19 MAR
Polish 8.0 KB
2025-08-08 20:29
Report Publication Announcement
Zawiadomienie od osoby zobowiązanej - Content (PL)
Polish 213 bytes
2025-07-15 12:07
Business and Financial Review
Podpisanie znaczącej umowy - Content (PL)
Polish 581 bytes
2025-06-27 14:00
Regulatory News Service
Podpisanie znaczącej umowy - Content (PL)
Polish 776 bytes
2025-06-25 13:05
Major Shareholding Notification
zal01_Wykaz_akcjonariuszy.pdf
Polish 127.8 KB
2025-06-25 13:05
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających co najmniej 5% głosów podczas WZ w dniu 25.6.…
Polish 242 bytes
2025-06-25 13:03
Post-Annual General Meeting Information
Uchwały wraz z informacjami.
Polish 244.6 KB
2025-06-25 13:03
Post-Annual General Meeting Information
Uchwały podjęte podcza Walnego Zgromadzenia w dniu 25.6.2025 - Content (PL)
Polish 440 bytes
2025-06-05 12:18
Director's Dealing
zal01_powiadomienie_o_nabyciu_akcji_5_06_2025.pdf
Polish 6.0 KB
2025-06-05 12:18
Board/Management Information
Zawiadomienie od osoby zobowiązanej - Content (PL)
Polish 239 bytes
2025-05-30 17:01
Quarterly Report
Skonsolidowane sprawozdanie finansowe wraz z jednostkową informacją finansową
Polish 1.2 MB
2025-05-29 20:55
Remuneration Information
Sprawodanie o wynagrodzeniach
Polish 2.0 MB
2025-05-29 20:55
Business and Financial Review
Sprawozdanie Rady Nadzorczej
Polish 3.0 MB
2025-05-29 20:55
Pre-Annual General Meeting Information
Zawiadomienie o zwołaniu WZ wraz z projektami uchwał
Polish 315.6 KB

Automate Your Workflow. Get a real-time feed of all BioMaxima S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for BioMaxima S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
MEDICOX Co., Ltd. Logo
Developing new drugs and building a distribution platform for healthcare solutions.
South Korea 054180
Medigene AG Logo
Clinical-stage immuno-oncology firm developing TCR-engineered T cell therapies for solid tumors.
Germany MDG1
MedinCell S.A. Logo
Develops long-acting injectable therapies using proprietary technology to impact global health.
France MEDCL
A CDMO for cell therapy and regenerative medicine development & manufacturing.
Japan 2370
Medios AG Logo
Compounding patient-specific therapies and supplying specialty pharma for complex conditions.
Germany ILM1
Develops cord blood stem cell therapies for osteoarthritis & infant lung disease, plus banking.
South Korea 078160
Medizen Humancare Inc Co., Ltd Logo
Offers DTC genetic testing and genomic analysis for personalized disease risk prediction.
South Korea 236340
Medy-Tox Inc. Logo
Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.
South Korea 086900
Meito  Sangyo  Co., Ltd. Logo
Produces food products and specialty chemicals for industrial and pharmaceutical applications.
Japan 2207
Merck KGaA Logo
A science & tech firm in healthcare, life science, and electronics, advancing human progress.
United States of America 6MK

Talk to a Data Expert

Have a question? We'll get back to you promptly.